{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:42:45Z","timestamp":1788903765934,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Understanding how patients are treated in the real-world is vital to identifying potential gaps in care. We describe the current pharmacologic treatment patterns for the treatment of depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with depression were identified from four large national claims databases during 1\/1\/2014\u20131\/31\/2019. Patients had \u22652 diagnoses for depression or an inpatient hospitalization with a diagnosis of depression. Patients were required to have enrollment in the database \u22651\u2009year prior to and 3 years following their first depression diagnosis. Treatment patterns were captured at the class level and included selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, other antidepressants, anxiolytics, hypnotics\/sedatives, and antipsychotics. Treatment patterns were captured during all available follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 269,668 patients diagnosed with depression. The proportion not receiving any pharmacological treatment during follow-up ranged from 29 to 52%. Of the treated, approximately half received \u22652 different classes of therapy, a quarter received \u22653 classes and more than 10% received 4 or more. SSRIs were the most common first-line treatment; however, many patients received an anxiolytic, hypnotic\/sedative, or antipsychotic prior to any antidepressive treatment. Treatment with a combination of classes ranged from approximately 20% of first-line therapies to 40% of fourth-line.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Many patients diagnosed with depression go untreated and many others receive a non-antidepressant medication class as their first treatment. More than half of patients received more than one type of treatment class during the study follow up, suggesting that the first treatment received may not be optimal for most patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-019-2418-7","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T08:02:51Z","timestamp":1578038571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-3925","authenticated-orcid":false,"given":"David M.","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Soledad","family":"Cepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Defalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Etropolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"2418_CR1","unstructured":"National Institute of Mental Health. Major Depression 2019 [Last Accessed: September 9, 2019]. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression.shtml."},{"issue":"2","key":"2418_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0193-953X(02)00107-7","volume":"26","author":"M Fava","year":"2003","unstructured":"Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457\u201394 x.","journal-title":"Psychiatr Clin North Am"},{"issue":"9","key":"2418_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/ijnp\/pyx043","volume":"20","author":"M Adli","year":"2017","unstructured":"Adli M, Wiethoff K, Baghai TC, Fisher R, Seemuller F, Laakmann G, et al. How effective is algorithm-guided treatment for depressed inpatients? Results from the randomized controlled multicenter German algorithm project 3 trial. Int J Neuropsychopharmacol. 2017;20(9):721\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 6","key":"2418_CR4","first-page":"22","volume":"62","author":"MH Trivedi","year":"2001","unstructured":"Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62(Suppl 6):22\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2418_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","volume":"75","author":"BN Gaynes","year":"2008","unstructured":"Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57\u201366.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2418_CR6","first-page":"134","volume":"25","author":"P Wang","year":"2013","unstructured":"Wang P, Si T. Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry. 2013;25(3):134\u201340.","journal-title":"Shanghai Arch Psychiatry"},{"issue":"3","key":"2418_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","volume":"52","author":"S-M Wang","year":"2016","unstructured":"Wang S-M, Han C, Lee S-J, Jun T-Y, Patkar AA, Masand PS, et al. Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 2016;52(3):159\u201372.","journal-title":"Chonnam Med J"},{"issue":"4","key":"2418_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1062860606288243","volume":"21","author":"LI Solberg","year":"2006","unstructured":"Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238\u201345.","journal-title":"Am J Med Qual"},{"issue":"10","key":"2418_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","volume":"46","author":"PS Romano","year":"1993","unstructured":"Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075\u201390.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2418_CR10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/jamia\/ocy124","volume":"25","author":"G Hripcsak","year":"2018","unstructured":"Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc. 2018;25(12):1618\u201325.","journal-title":"J Am Med Inform Assoc"},{"key":"2418_CR11","unstructured":"SNOMED CT. SNOMED CT 5-Step Briefing 2019. Available from: http:\/\/www.snomed.org\/snomed-ct\/five-step-briefing."},{"issue":"9","key":"2418_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","volume":"153","author":"PE Stang","year":"2010","unstructured":"Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600\u20136.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2418_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12888-017-1385-0","volume":"17","author":"G Gauthier","year":"2017","unstructured":"Gauthier G, Gu\u00e9rin A, Zhdanava M, Jacobson W, Nomikos G, Merikle E, et al. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. BMC Psychiatry. 2017;17(1):222.","journal-title":"BMC Psychiatry"},{"issue":"27","key":"2418_CR14","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1073\/pnas.1510502113","volume":"113","author":"G Hripcsak","year":"2016","unstructured":"Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2418_CR15","unstructured":"American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Major Depressive Disorder 2010 [Last Accessed: August 19, 2019]. Available from: https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf."},{"issue":"7","key":"2418_CR16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9078tx1c","volume":"71","author":"AJ Gelenberg","year":"2010","unstructured":"Gelenberg AJ. A review of the current guidelines for depression treatment. J Clin Psychiatry. 2010;71(7):e15.","journal-title":"J Clin Psychiatry"},{"issue":"519","key":"2418_CR17","first-page":"755","volume":"55","author":"J Hyde","year":"2005","unstructured":"Hyde J, Calnan M, Prior L, Lewis G, Kessler D, Sharp D. A qualitative study exploring how GPs decide to prescribe antidepressants. Br J Gen Pract. 2005;55(519):755\u201362.","journal-title":"Br J Gen Pract"},{"issue":"6","key":"2418_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/0269881106072386","volume":"21","author":"C Haw","year":"2007","unstructured":"Haw C, Stubbs J. Benzodiazepines--a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol. 2007;21(6):645\u20139.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2418_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1471-2296-14-191","volume":"14","author":"C Sirdifield","year":"2013","unstructured":"Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T, Siriwardena AN. General practitioners\u2019 experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesis. BMC Fam Pract. 2013;14(1):191.","journal-title":"BMC Fam Pract"},{"issue":"5","key":"2418_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152\u20135.","journal-title":"Aust Prescr"},{"issue":"12","key":"2418_CR21","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011;106(12):2086\u2013109.","journal-title":"Addiction"},{"key":"2418_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"2418_CR23","doi-asserted-by":"publisher","first-page":"A48","DOI":"10.1186\/1940-0640-10-S1-A48","volume":"10","author":"TW Park","year":"2015","unstructured":"Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and drug overdose mortality among individuals receiving opioid analgesics. Addict Sci Clin Pract. 2015;10(1):A48.","journal-title":"Addict Sci Clin Pract"},{"key":"2418_CR24","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","volume":"356","author":"EC Sun","year":"2017","unstructured":"Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.","journal-title":"BMJ."},{"issue":"10","key":"2418_CR25","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1001\/jamainternmed.2016.5057","volume":"176","author":"M Olfson","year":"2016","unstructured":"Olfson M, Blanco C, Marcus SC. Treatment of adult depression in the United States. JAMA Intern Med. 2016;176(10):1482\u201391.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2418_CR26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4088\/JCP.15m10267","volume":"77","author":"MS Cepeda","year":"2016","unstructured":"Cepeda MS, Stang P, Makadia R. Depression is associated with high levels of C-reactive protein and low levels of fractional exhaled nitric oxide: results from the 2007-2012 National Health and nutrition examination surveys. J Clin Psychiatry. 2016;77(12):1666\u201371.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2418_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/M15-2570","volume":"164","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Barry MJ, Kansagara D. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164(5):350\u20139.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2418_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.5664\/jcsm.5876","volume":"12","author":"MS Cepeda","year":"2016","unstructured":"Cepeda MS, Stang P, Blacketer C, Kent JM, Wittenberg GM. Clinical relevance of sleep duration: results from a cross-sectional analysis using NHANES. J Clin Sleep Med. 2016;12(6):813\u20139.","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"2418_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-017-0417-0","volume":"31","author":"KR Keyloun","year":"2017","unstructured":"Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD). CNS drugs. 2017;31(5):421\u201332.","journal-title":"CNS drugs"},{"issue":"1","key":"2418_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101\u20138.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"2418_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/ijcp.12850","volume":"70","author":"JP Fagot","year":"2016","unstructured":"Fagot JP, Cuerq A, Samson S, Fagot-Campagna A. Cohort of one million patients initiating antidepressant treatment in France: 12-month follow-up. Int J Clin Pract. 2016;70(9):744\u201351.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"2418_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222791","volume":"14","author":"MJ Kim","year":"2019","unstructured":"Kim MJ, Kim N, Shin D, Rhee SJ, Park CHK, Kim H, et al. The epidemiology of antidepressant use in South Korea: does short-term antidepressant use affect the relapse and recurrence of depressive episodes? PLoS One. 2019;14(9):e0222791.","journal-title":"PLoS One"},{"issue":"2","key":"2418_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00127-016-1306-4","volume":"52","author":"B Mars","year":"2017","unstructured":"Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on antidepressant prescribing trends in the UK: 1995-2011. Soc Psychiatry Psychiatr Epidemiol. 2017;52(2):193\u2013200.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-019-2418-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T19:14:09Z","timestamp":1609528449000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2418-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2418"],"URL":"https:\/\/doi.org\/10.1186\/s12888-019-2418-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.16047\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16047\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16047\/v2","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of the databases was reviewed by the New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subjects research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Janssen Research & Development, LLC, which markets and develops treatments for depression, and are stockholders of Johnson & Johnson, Janssen\u2019s parent company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}